Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio reports developments from its clinical-stage biopharmaceutical pipeline of Natural Killer T cell modulators for inflammatory, fibrotic and autoimmune diseases. Recurring updates center on GRI-0621, an RARβγ agonist being developed as an oral therapy for idiopathic pulmonary fibrosis, including Phase 2a clinical, biomarker, immune-profiling and gene-expression data.
The company also issues news on GRI-0803 and other type 2 diverse NKT agonist programs, patents covering dNKT agonists and novel compound compositions, its proprietary compound library, financial results, equity financings, Nasdaq compliance matters, reverse stock split actions and conference participation.
Summary not available.
Summary not available.
Summary not available.
GRI Bio, Inc. (NASDAQ: GRI) has appointed Leanne Kelly as Chief Financial Officer. With over 20 years of experience in finance, particularly in life sciences and technology, Kelly previously held the CFO role at Vallon Pharmaceuticals, which recently merged with GRI Bio. Her expertise in public and private markets was deemed essential as GRI transitions post-merger.
CEO Marc Hertz expressed confidence in Kelly's capabilities to strengthen the company's financial position and presence in the investment community. GRI Bio focuses on innovative therapies targeting inflammatory and autoimmune diseases, with promising developments like GRI-0621 for idiopathic pulmonary fibrosis.
GRI Bio, Inc. (NASDAQ: GRI) has announced significant advancements following its merger with Vallon Pharmaceuticals, effective April 24, 2023. The company has appointed three industry veterans—David Szekeres as Chairman, Roelof Rongen, and Camilla V. Simpson—to its Board of Directors, marking a pivotal transformation.
GRI Bio focuses on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases. Their lead program, GRI-0621, aims to treat idiopathic pulmonary fibrosis, a condition with critical unmet needs. With a library of over 500 proprietary compounds, GRI is well-positioned for future growth in the biopharmaceutical market.